Ladprao General Hospital PCL

Ladprao General Hospital maintains a conservative capital structure with a debt-to-equity ratio of 0.19, significantly below the industry median of 0.45, indicating a strong equity position and limited leverage. The company's liquidity position is characterized by a current ratio of 1.54, which is in line with the industry median of 1.50, suggesting adequate short-term liquidity to meet obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints in the near term. Profitability metrics show that the company generates a return on equity (ROE) of 10.02%, which is below the industry median of 12.50%, and a return on assets (ROA) of 6.68%, also below the industry median of 8.20%. This suggests that the company is underperforming its peers in terms of asset utilization and equity returns. Gross profit margin stands at 28.56%, compared to the industry median of 32.00%, indicating room for improvement in cost control or pricing power. The company operates through two segments: Hospital and Scientific Laboratory Testing & Research. The Hospital segment accounts for the majority of revenue, with the Scientific Laboratory segment contributing a smaller but growing portion. Geographically, the company is concentrated in Thailand, with no material international revenue disclosed in the latest financials. This concentration increases exposure to local economic and regulatory risks. Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next fiscal year, based on historical trends and industry demand for healthcare services. However, the growth rate is modest compared to the industry median of 6.5% for the current year and 5.8% for the next year. The company's capital expenditure is negative at -132.89 million THB, indicating asset disposals or reduced investment in infrastructure. Risk factors include the company's reliance on government and social security contracts, which are subject to policy changes and funding fluctuations. Additionally, the negative net cash position raises concerns about liquidity risk, particularly if operating cash flow does not improve. The company's dilution risk is currently low, as shares outstanding have not changed between basic and diluted counts, and no recent equity issuance or shelf registration has been disclosed. Recent events include the continued expansion of the Scientific Laboratory Testing & Research segment, which is expected to drive future revenue diversification. The company has also maintained stable operations despite macroeconomic headwinds in Thailand, with no material adverse events reported in the latest filings.